PRDM9 and cancer: Accordingly, InhiTinib may target: (i) the unfolded protein response by binding to heat shock factor 1 protein, (ii) the epigenome of cancer cells via histone methyltransferases modulation, and/or (iii) reduce antioxidant defenses by inhibiting thioredoxin reductase activity.